Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
10
×
life sciences
10
×
national blog main
san francisco
10
×
san francisco blog main
10
×
san francisco top stories
biotech
startups
boston blog main
boston top stories
national top stories
new york blog main
investing
new york top stories
san diego blog main
cancer
medical device
raleigh-durham blog main
san diego top stories
10x genomics
clinical trials
gene therapy
ipo
lung cancer
medical devices
roboticsai
roche
seattle blog main
seattle top stories
software
third rock ventures
vc
warp drive bio
accelerator
acetylon pharmaceuticals
adeno-associated virus
airbnb
alexandria venture investments
alphabet
altitude life science ventures
What
deal
big
expand
help
bio
biotech
companies
despite
diagnostics
drug
ipo
life
lung
make
medical
medicines
startup
tests
therapy
today
treatment
ability
acquire
adding
admits
ago
aiming
aims
ambys
array
auris
available
babies
based
biosciences
biotechs
boost
building
business
cancer
Language
unset
Current search:
deals
×
" san francisco blog main "
×
" san francisco "
×
" life sciences "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
Auris Health Lands $220M to Expand Sales of Lung Testing Medical Robot
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed